AAV-EFlα-DIO-iGluSnFR4S-NGR

Research background

This AAV supports optical measurement of neuromodulator or neurotransmitter dynamics using a genetically encoded sensor. These sensors translate ligand binding into fluorescence changes, enabling real-time monitoring of extracellular signaling.

Mechanism and expected readouts

Sensor expression at the membrane or targeted compartment provides fluorescence responses that track ligand concentration changes over time. Quantitative interpretation often involves calibration, attention to kinetics/affinity, and control for pH or motion artifacts depending on sensor class.

Expression design and interpretation

Expression is driven by the EFlα promoter, which determines where and how strongly the payload is expressed in your system (cell populations defined by the listed promoter). The construct's regulatory logic controls where/when the payload is active; Cre-dependent control restricts expression to cells expressing Cre recombinase. The encoded payload is intended to support the stated experimental function (e.g., modulation, sensing, labeling, or control). Glutamate sensors report fast glutamatergic signaling, supporting synaptic transmission studies.

Subcellular targeting elements (when present) can bias localization and should be confirmed by imaging in your preparation.

Common research applications

• In vivo monitoring of neuromodulator release during behavior
• Pharmacology and receptor pathway studies in slices or culture
• Circuit-state tracking alongside optogenetic or electrophysiological perturbations

Experimental considerations

• Match sensor affinity/kinetics to expected concentration ranges and event durations
• Consider co-expression strategy if pairing with actuators or reference fluorophores
• Validate subcellular localization to ensure the sensor reports the intended compartment

Controls and validation

Typical validation includes confirming expression pattern and level, verifying functional activity with an assay matched to the payload (e.g., imaging, electrophysiology, pharmacology, or behavior), and using appropriate negative controls.

• Sales Terms and Conditions (PDF)
• SDS (PDF)

At present, the main purification approaches for rAAV include:

• Ultracentrifugation density-gradient methods, using cesium chloride (CsCl) or iodixanol as the gradient medium;
• Chemical reagent precipitation/extraction methods, mainly using PEG, ammonium sulfate, chloroform, etc.;
• Chromatographic purification methods, primarily based on affinity and ion-exchange principles.

Depending on customers’ different application needs, we can integrate multiple methods to produce high-titer, high-purity, high-quality rAAV viral products.

Can’t find the AAV you need—or require a custom design and packaging service? We offer end-to-end support for diverse research and therapeutic needs, including vector design and cloning, AAV packaging services (serotype/capsid selection and production), QC & characterization (project-appropriate testing and documentation), and library preparation for pooled or library-style workflows (project dependent). Click Talk to a Scientist to submit a request form, email us at support@biohippo.com, or explore our Research Services for additional support. Our team will be in contact with you shortly.